7 results about "Tetanus Toxins" patented technology

The application discloses a multivalent biological toxin antigen vaccine based on double receptor binding domain (RBD) assembly and a preparation method and application thereof. The application provides a multivalent biological toxin molecular antigen vaccine, and an active ingredient of the vaccine is a fusion protein formed by connecting an Hc protective antigen of biological toxin 1 and an Hc protective antigen of biological toxin 2 through a connecting peptide; the biological toxin 1 and the biological toxin 2 are two different biological toxins; and the biological toxin is selected from the following: tetanus toxin or other types of botulinum toxin (including types A, B and H) except type E. The application proves that different serotypes of botulinum toxin and tetanus toxin receptor binding domain Hc antigens are fused and assembled into a double Hc fusion antigen molecule by using genetic engineering and biosynthesis technology, and the double Hc fusion antigen molecule can generate strong protection against multiple biological toxins as a single subunit vaccine. Therefore, the Hc fusion antigen molecule vaccine of the application can generate protection against multiple different serotypes of biological toxin pathogens, and can be used as a broad-spectrum multivalent vaccine for biological toxin prevention and preventive treatment.

The present disclosure provides an anti-tetanus toxin neutralizing antibody as a new generation of tetanus passive immunization preparation. The antibody can be fully human, which can specifically bind to full-length tetanus toxin and its AB fragment, has high affinity, high specificity, small toxic side effects, avoids the problems of large adverse reactions and short half-life of animal-derived monoclonal antibodies, and is prepared in large quantities by mammalian cells, and has clear and stable components.

Disclosed in the present invention is a formulation containing an anti-tetanus toxin antibody, wherein the formulation comprises the anti-tetanus toxin antibody at a concentration of 1-100 mg / mL, and has a pH of 5.0-7.0; and optionally, the formulation further comprises one or more of a surfactant, a pH regulator, a protein protective agent, and an osmotic pressure regulator. The formulation provided by the present invention can effectively maintain the stability of the antibody, so that the antibody is not liable to aggregate, thereby preventing oxidation, denaturation and degradation. In addition, the formulation also maintains the high titer of the antibody against tetanus toxin, and thus has the high biological activity required for preventing or treating tetanus.

Provided are a bispecific antibody and a monoclonal antibody for a tetanus toxin, and uses of the antibodies. The bispecific antibody contains a first antigen-binding fragment and a second antigen-binding fragment which bind to different epitopes of the tetanus toxin, and has activity of neutralizing the tetanus toxin. The monoclonal antibody binds to the tetanus toxin, and has activity of neutralizing the tetanus toxin.

The application discloses a preparation containing an anti-tetanus toxin antibody, the preparation containing the anti-tetanus toxin antibody at a concentration of 1-100 mg / mL and having a pH of 5.0-7.0; and optionally, the preparation further contains one or more of a surfactant, a pH regulator, a protein protective agent and an osmotic pressure regulator. The preparation provided by the application can effectively maintain the stability of the antibody, so that the antibody is not prone to aggregation, oxidation, denaturation and degradation; in addition, the antibody has a high titer of anti-tetanus toxin and high bioactivity required for preventing or treating tetanus.

Provided is an application of an anti-tetanus toxin antibody in preventing or treating tetanus. The anti-tetanus toxin antibody is applied in a specific administration regimen, and can achieve the technical effects of being quicker to take effect and having a longer protection time than existing passive immunization agents, and can therefore effectively prevent or treat tetanus.